{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:13:51Z","timestamp":1792084431908,"version":"4.4.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Competent T-cells with sufficient levels of fitness combat cancer formation and progression. In multiple myeloma (MM), T-cell exhaustion is caused by several factors including tumor burden, constant immune activation due to chronic disease, age, nutritional status, and certain MM treatments such as alkylating agents and proteasome inhibitors. Many currently used therapies, including bispecific T-cell engagers, anti-CD38 antibodies, proteasome inhibitors, and CART-cells, directly or indirectly depend on the anti-cancer activity of T-cells. Reduced T-cell fitness not only diminishes immune defenses, increasing patient susceptibility to opportunistic infections, but can impact effectiveness MM therapy effectiveness, bringing into focus sequencing strategies that could modulate T-cell fitness and potentially optimize overall benefit and clinical outcomes. Certain targeted agents used to treat MM, such as selective inhibitors of nuclear export (SINE) compounds, have the potential to mitigate T-cell exhaustion. Herein referred to as XPO1 inhibitors, SINE compounds inhibit the nuclear export protein exportin 1 (XPO1), which leads to nuclear retention and activation of tumor suppressor proteins and downregulation of oncoprotein expression. The XPO1 inhibitors selinexor and eltanexor reduced T-cell exhaustion in cell lines and animal models, suggesting their potential role in revitalizating these key effector cells. Additional clinical studies are needed to understand how T-cell fitness is impacted by diseases and therapeutic factors in MM, to potentially facilitate the optimal use of available treatments that depend on, and impact, T-cell function. This review summarizes the importance of T-cell fitness and the potential to optimize treatment using T-cell engaging therapies with a focus on XPO1 inhibitors.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1275329","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T12:02:01Z","timestamp":1698321721000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors"],"prefix":"10.3389","volume":"14","author":[{"given":"Adam F.","family":"Binder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer M.","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"B1","unstructured":"Cancer Statistics Center: Myeloma"},{"key":"B2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2020.01243","article-title":"CAR T-cells in multiple myeloma: state of the art and future directions","volume":"10","author":"Rodr\u00edguez-Lobato","year":"2020","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E575","DOI":"10.1097\/HS9.0000000000000575","article-title":"Understanding the mechanisms of resistance to T cell-based immunotherapies to develop more favorable strategies in multiple myeloma","volume":"5","author":"Ahn","year":"2021","journal-title":"Hemasphere"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.780442\/BIBTEX","article-title":"T cell fitness and autologous CAR T cell therapy in haematologic Malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/J.EBIOM.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s2152-2650(22)00349-4","article-title":"P-019: Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed\/refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-cel)","volume":"22","author":"Rytlewski","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134369","article-title":"Effects of prior alkylating therapies on preinfusion patient characteristics and starting material for CAR T cell product manufacturing in late-line multiple myeloma","volume":"136","author":"Rytlewski","year":"2020","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163","article-title":"Clinical dosing regimen of selinexor maintains normal immune homeostasis and T-cell effector function in Mice: Implications for combination with immunotherapy","volume":"16","author":"Tyler","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-164443","article-title":"Sequential administration of selinexor then CD19 CAR-T cells exhibits enhanced efficacy in a mouse model of human non-Hodgkin\u2019s lymphoma","volume":"140","author":"Stadel","year":"2022","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/JHA2.572","article-title":"Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment","volume":"3","author":"Baljevic","year":"2022","journal-title":"EJHaem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/NI.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: Overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-21-0157","article-title":"Allogeneic anti-BCMA CAR T cells are superior to multiple myeloma-derived CAR T cells in preclinical studies and may be combined with gamma secretase inhibitors","volume":"2","author":"Metelo","year":"2022","journal-title":"Cancer Res Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4110\/IN.2022.22.E6","article-title":"CAR T cell immunotherapy beyond haematological Malignancy","volume":"22","author":"Hupperetz","year":"2022","journal-title":"Immune Netw"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1152498","article-title":"Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell Malignancies","volume":"14","author":"Garc\u00eda-Calder\u00f3n","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.114025","article-title":"Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies","volume":"100","author":"Teh","year":"2015","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/PH15020207","article-title":"The past, present, and future of clinically applied chimeric antigen receptor-T-cell therapy","volume":"15","author":"Fujiwara","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0002","article-title":"Multiple myeloma, version 3.2022: featured updates to the NCCN guidelines","volume":"20","author":"Callander","year":"2022","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"B25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1186\/s12879-019-4545-7","article-title":"Disseminated cytomegalovirus disease after bendamustine: A case report and analysis of circulating B- and T-cell subsets","volume":"19","author":"Cona","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/BLCTT.S327016","article-title":"CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"B28","unstructured":"PharmaceuticalsM\n          Prescribing Information | VELCADE\u00ae (bortezomib)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01172-x","article-title":"Selective elimination of immunosuppressive T cells in patients with multiple myeloma","volume":"35","author":"Awwad","year":"2021","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2018-99-117531","article-title":"Immunome single cell profiling reveals T cell exhaustion with upregulation of checkpoint inhibitors LAG3 and tigit on marrow infiltrating T lymphocytes in daratumumab and IMiDs resistant patients","volume":"132","author":"Neri","year":"2018","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/ELIFE.62420","article-title":"The effects of age and systemic metabolism on anti-tumor T cell responses","volume":"9","author":"Drijvers","year":"2020","journal-title":"Elife"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/nu13061980","article-title":"The spectrum of malnutrition\/cachexia\/sarcopenia in oncology according to different cancer types and settings: A narrative review","volume":"13","author":"Bossi","year":"2021","journal-title":"Nutrients"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646423","article-title":"Nutritional effects on T-cell immunometabolism","volume":"47","author":"Cohen","year":"2017","journal-title":"Eur J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04672-8","article-title":"Mitochondrial dysfunction and drug targets in multiple myeloma","volume":"10","author":"Cui","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0110","article-title":"Mitochondria as playmakers of CAR T-cell fate and longevity","volume":"9","author":"Rostamian","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.1c00022","article-title":"Metabolic changes are associated with melphalan resistance in multiple myeloma","volume":"20","author":"Koomen","year":"2021","journal-title":"J Proteome Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/ijms23031760","article-title":"Synthesis and in vitro activity of novel melphalan analogs in hematological Malignancy cells","volume":"23","author":"Poczta","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0206","article-title":"CD4 T-cell exhaustion: does it exist and what are its roles in cancer","volume":"27","author":"Miggelbrink","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12517","article-title":"Mastering an exhausting marathon: how CD8+ T cells fine-tune metabolic fitness","volume":"100","author":"Schulz","year":"2022","journal-title":"Immunol Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.06.018","article-title":"IMiDs: a novel class of immunomodulators","volume":"32","author":"Knight","year":"2005","journal-title":"Semin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: Results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6199","article-title":"Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis","volume":"10","author":"Lakritz","year":"2022","journal-title":"Clin Case Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1017990","article-title":"Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms","volume":"13","author":"Guo","year":"2022","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and review of the literature","volume":"71","author":"Zhao","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/J.CELL.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMOA2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2022017848\/1928339\/BLOOD.2022017848.PDF","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2022","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/LEU.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/SIGTRANS.2016.10","article-title":"Inhibiting cancer cell hallmark features through nuclear export inhibition","volume":"1","author":"Sun","year":"2016","journal-title":"Signal Transduct Target Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/SCI.2019.02.03","article-title":"The past, present, and future of CRM1\/XPO1 inhibitors","volume":"6","author":"Wang","year":"2019","journal-title":"Stem Cell Investig"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELREP.2012.07.007","article-title":"The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation","volume":"2","author":"Culjkovic-Kraljacic","year":"2012","journal-title":"Cell Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANTIVIRAL.2021.105115","article-title":"Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo","volume":"192","author":"Kashyap","year":"2021","journal-title":"Antiviral Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2443.2012.01607.X","article-title":"Ligand-dependent nucleo-cytoplasmic shuttling of peroxisome proliferator-activated receptors, PPAR\u03b1 and PPAR\u03b3","volume":"17","author":"Umemoto","year":"2012","journal-title":"Genes to Cells"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/ME.2001-0345","article-title":"Retinoid X receptor dominates the nuclear import and export of the unliganded vitamin D receptor","volume":"16","author":"Pr\u00fcfer","year":"2002","journal-title":"Mol Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBRC.2018.07.112","article-title":"KPT-330, a potent and selective CRM1 inhibitor, exhibits anti-inflammation effects and protection against sepsis","volume":"503","author":"Wu","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01684-18","article-title":"Verdinexor (KPT-335), a selective inhibitor of nuclear export, reduces respiratory syncytial virus replication","volume":"93","author":"Jorquera","year":"2019","journal-title":"In Vitro J Virol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-98767-2","article-title":"Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication","volume":"11","author":"Mathew","year":"2021","journal-title":"Sci Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"10228","DOI":"10.1128\/JVI.01774-14","article-title":"Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza A virus replication in vitro and in vivo","volume":"88","author":"Perwitasari","year":"2014","journal-title":"J Virol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102400","article-title":"Next-generation SINE compound KPT\u20138602 ameliorates dystrophic pathology in zebrafish and mouse models of DMD","volume":"10","author":"English","year":"2022","journal-title":"Biomedicines"},{"key":"B64","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3892\/or.2021.8121","article-title":"Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive Malignancies","volume":"46","author":"Wang","year":"2021","journal-title":"Oncol Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e20034","article-title":"Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment","volume":"41","author":"Baljevic","year":"2023","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1182\/blood-2019-128887","article-title":"Selinexor-containing regimens for the treatment of patients with multiple myeloma refractory to chimeric antigen receptor T-cell (CAR-T) therapy","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.00940","article-title":"The tumor microenvironment: A milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632399","article-title":"Understanding the role of T-cells in the antimyeloma effect of immunomodulatory drugs","volume":"12","author":"D\u2019Souza","year":"2021","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01608-2","article-title":"Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients","volume":"126","author":"Gasparetto","year":"2022","journal-title":"Br J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148759","article-title":"Once weekly oral selinexor, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma","volume":"138","author":"White","year":"2021","journal-title":"Blood"},{"key":"B71","unstructured":"NCCN GUIDELINES FOR PATIENTS \u00ae Multiple Myeloma2021"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","author":"Mohan","year":"2023","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1275329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T12:02:08Z","timestamp":1698321728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1275329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":72,"alternative-id":["10.3389\/fimmu.2023.1275329"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1275329","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"article-number":"1275329"}}